Compounds > pyrroles
Page last updated: 2024-08-18

pyrroles and dactolisib

pyrroles has been researched along with dactolisib in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Auernhammer, CJ; Brand, S; Göke, B; Lichtl, J; Rüden, Jv; Spöttl, G; Zitzmann, K1
Buet, D; Denis, N; Dusanter-Fourt, I; Gallais, I; Guillonneau, F; Guillouf, C; Kosmider, O; Lauret, E; Loew, D; Lombard, B; Mayeux, P; Moreau-Gachelin, F1
Alusi, G; Garcia, E; Giubellino, A; Grossman, AB; Korbonits, M; Nölting, S; Pacak, K1
de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A1
Chumduri, C; Daniel, PT; Dörken, B; Müller, A; Scholz, CW; Zang, C1
Cheng, AL; Hsu, C; Lee, BS; Liao, SC; Lin, LI; Liou, JY; Ou, DL1
Byun, SS; Cheon, J; Hong, SK; Jeong, SJ; Lee, SE; Moon, du G; Oh, MM; Park, HS; Yoon, CY1
Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU1
Jeong, BC; Kim, H; Lee, IK; Lee, J; Lee, SJ; Min, SC; Park, SH; Sung, HH1

Other Studies

9 other study(ies) available for pyrroles and dactolisib

ArticleYear
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Cancer letters, 2010, Sep-01, Volume: 295, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; G1 Phase; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; raf Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
    Blood, 2012, May-03, Volume: 119, Issue:18

    Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Indoles; Leukemia, Mast-Cell; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-kit; Pyrroles; Quinolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Tumor Stem Cell Assay

2012
Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
    Journal of molecular endocrinology, 2012, Volume: 49, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Everolimus; Extracellular Signal-Regulated MAP Kinases; Imidazoles; Lovastatin; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; PC12 Cells; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptor, IGF Type 1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2012
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2013
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    International journal of cancer, 2013, Oct-15, Volume: 133, Issue:8

    Topics: Amino Acid Chloromethyl Ketones; Antibiotics, Antineoplastic; Apoptosis; bcl-X Protein; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; Lymphoma, Mantle-Cell; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2013
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Molecular cancer, 2014, Jan-03, Volume: 13

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Everolimus; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptors, Somatomedin; Signal Transduction; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2014
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indoles; Male; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sunitinib; Taxoids; Vascular Endothelial Growth Factor Receptor-2

2014
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC cancer, 2017, Nov-03, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2017
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
    International journal of molecular sciences, 2020, Apr-18, Volume: 21, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Imidazoles; Inhibitory Concentration 50; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms

2020